Abstract
Appropriate subcellular localization of proteins is crucial for regulating their functions. Both p53 and the BH3- only Bid play roles in the development and the treatment of hepatocellular carcinoma (HCC). They both participate in the cross talk of cell cycle arrest and apoptosis in response to DNA damage. However, some important issues related to their pathways are not yet resolved. Bid genomic loci contain p53-binding DNA response elements and Bid can mediate p53- dependent transactivation. Here, we showed that etoposide-induced DNA damage could significantly induce p53 and Bid nuclear export. When cells were stimulated by etoposide, p53 could, through the association with Bid, cause translocation of Bid from the nucleus to the cytoplasm and on to its ultimate location in the mitochondria. p53 was physically associated with Bid, and both p53 and Bid cooperatively promoted cell death induced by etoposide. Knockdown of Bid expression notably attenuated cell death induced by etoposide and also released p53 from the mitochondria. These findings reveal a novel mechanism by which p53 is associated with Bid in the nucleus to facilitate exportation of Bid to the mitochondria and induce apoptosis in response to etoposide-induced DNA damage in HCC.
Keywords: Bid, p53, nucleus, mitochondria, etoposide, cell death, hepatocellular carcinoma
Current Cancer Drug Targets
Title: Association of p53 with Bid Induces Cell Death in Response to Etoposide Treatment in Hepatocellular Carcinoma
Volume: 9 Issue: 7
Author(s): G. Song, G. G. Chen, J.-P. Yun and P. B.S. Lai
Affiliation:
Keywords: Bid, p53, nucleus, mitochondria, etoposide, cell death, hepatocellular carcinoma
Abstract: Appropriate subcellular localization of proteins is crucial for regulating their functions. Both p53 and the BH3- only Bid play roles in the development and the treatment of hepatocellular carcinoma (HCC). They both participate in the cross talk of cell cycle arrest and apoptosis in response to DNA damage. However, some important issues related to their pathways are not yet resolved. Bid genomic loci contain p53-binding DNA response elements and Bid can mediate p53- dependent transactivation. Here, we showed that etoposide-induced DNA damage could significantly induce p53 and Bid nuclear export. When cells were stimulated by etoposide, p53 could, through the association with Bid, cause translocation of Bid from the nucleus to the cytoplasm and on to its ultimate location in the mitochondria. p53 was physically associated with Bid, and both p53 and Bid cooperatively promoted cell death induced by etoposide. Knockdown of Bid expression notably attenuated cell death induced by etoposide and also released p53 from the mitochondria. These findings reveal a novel mechanism by which p53 is associated with Bid in the nucleus to facilitate exportation of Bid to the mitochondria and induce apoptosis in response to etoposide-induced DNA damage in HCC.
Export Options
About this article
Cite this article as:
Song G., Chen G. G., Yun J.-P. and Lai B.S. P., Association of p53 with Bid Induces Cell Death in Response to Etoposide Treatment in Hepatocellular Carcinoma, Current Cancer Drug Targets 2009; 9 (7) . https://dx.doi.org/10.2174/156800909789760302
DOI https://dx.doi.org/10.2174/156800909789760302 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets The Disulfide Analogues of Isophosphoramide Mustard for Anticancer Therapy
Letters in Drug Design & Discovery Progresses in TCM Metal-Based Antitumour Agents
Anti-Cancer Agents in Medicinal Chemistry Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers
Current Cancer Drug Targets Immune Checkpoint Inhibitors in AML-A New Frontier
Current Cancer Drug Targets Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry Aptamer-Mediated Cancer Gene Therapy
Current Gene Therapy Thrombotic Microangiopathy and Occult Neoplasia
Cardiovascular & Hematological Disorders-Drug Targets Potential Beneficial Effects of Garlic in Oncohematology
Mini-Reviews in Medicinal Chemistry Targeted Drug Delivery: Trends and Perspectives
Current Drug Delivery MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Anticancer Immunotherapy in Combination with Proapoptotic Therapy
Current Cancer Drug Targets Cyclophilin function in Cancer; lessons from virus replication
Current Molecular Pharmacology Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Current Treatment Concepts of Philadelphia-Negative MPN
Current Cancer Drug Targets (Review Article) Screening for Disease-Markers and Investigating Drug Effects by Proteome Profiling: Can it Meet Expectations?
Combinatorial Chemistry & High Throughput Screening Induced Stem Cells as a Novel Multiple Sclerosis Therapy
Current Stem Cell Research & Therapy Energy Dependent Transport of Xenobiotics and Its Relevance to Multidrug Resistance
Current Cancer Drug Targets FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
Current Drug Targets